A prominent Boston oncologist is downplaying comments he made at an invitation-only event last week that quickly spread among investors and set off alarm bells about an experimental multiple myeloma cell therapy from Bluebird Bio (BLUE) and Celgene (CELG).

Dr. Ken Anderson, a multiple myeloma expert at the Dana-Farber Cancer Institute, told investors attending the Cowen Health Care Conference on March 13 that three patients under his care suffered relapses after treatment with bb2121, the CAR-T therapy invented by Bluebird and licensed to Celgene.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy